UPDATE: Needham On Celcuity Buy Initiation Earlier: Firm Sees Gedatolisib As Potential First-In-Class PI3K/mTOR Pathway Inhibitor Given 60% Objective Response Rate From Ongoing Phase 1B Trial; Notes Co. 'Could Broaden & Transform Targeted Cancer Therapy'